AGÕæÈ˹ٷ½

STOCK TITAN

Cytosorbents Corp SEC Filings

CTSO NASDAQ

Welcome to our dedicated page for Cytosorbents SEC filings (Ticker: CTSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading a medical-device firm’s disclosures can feel like a lab manual. CytoSorbents� filings pack clinical-trial data, FDA feedback, and grant accounting into hundreds of pages—just when you need quick answers. If you have ever searched for “CytoSorbents SEC filings explained simply,� this page is your direct route to clarity.

Stock Titan applies AI to every document the moment it hits EDGAR. That means you can open a CytoSorbents quarterly earnings report 10-Q filing and see cash-burn highlights in seconds, or scan CytoSorbents Form 4 insider transactions real-time to spot when executives adjust their stakes. Whether you are comparing R&D spend across quarters or decoding an 8-K about a new FDA IDE, our summaries turn technical language into actionable insight.

Below you will find every form, updated the instant it’s published, along with context on why it matters:

  • CytoSorbents insider trading Form 4 transactions â€� follow buying or selling linked to clinical milestones.
  • CytoSorbents earnings report filing analysis â€� AI pulls revenue from EU sales, grant income, and trial costs.
  • CytoSorbents annual report 10-K simplified â€� understand polymer-adsorption technology, patents, and risk factors without wading through 300 pages.
  • CytoSorbents proxy statement executive compensation â€� see how incentive plans align with pivotal study outcomes.
  • CytoSorbents executive stock transactions Form 4 â€� track patterns ahead of material announcements.
  • CytoSorbents 8-K material events explained â€� instant context on trial results, CE-Mark renewals, or government contracts.
  • Guides for understanding CytoSorbents SEC documents with AI, including glossaries and metric trackers.

From real-time alerts to plain-language briefs, Stock Titan equips you to act on new information faster than anyone still scrolling through PDFs.

Rhea-AI Summary

MGIC Investment Corp. (MTG) � Form 4 insider transaction

President & COO Salvatore A. Miosi disclosed the sale of 30,000 shares of common stock on 01-Jul-2025 at a weighted-average price of $28.152 per share, generating roughly $0.84 million in proceeds. The disposition was executed under a Rule 10b5-1 trading plan adopted on 06-Mar-2025, indicating the sale was pre-scheduled and not necessarily driven by near-term information.

After the transaction, Miosi directly owns 279,401.361 shares and indirectly controls 384,844 shares via a family trust, maintaining a sizable equity stake. No derivative security activity was reported, and the filing contains no references to earnings, major corporate events, or strategic changes.

The filing primarily records a routine adjustment to the executive’s equity exposure; in isolation, it is unlikely to materially affect the company’s fundamental outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

CytoSorbents Corporation (Nasdaq: CTSO) filed a Form 8-K on June 24, 2025 to disclose a material regulatory development. Under Item 8.01 â€� Other Events, the company reported that it has decided to appeal the U.S. Food & Drug Administration’s (FDA) denial letter related to its De Novo request for DrugSorb-ATR, a blood purification device designed to remove antithrombotic agents during cardiothoracic surgery. The filing furnishes a press release (Exhibit 99.1) as additional detail; however, that release is not included in the body of the 8-K.

The appeal process indicates that management believes there are sufficient grounds to contest the FDA’s decision, but the 8-K offers no timetable, data, or probability of success. No sales, earnings, or forecast information is provided, and no other corporate actions (financing, partnerships, leadership changes) are mentioned. Investors should note that DrugSorb-ATR represents an important U.S. commercial opportunity for CTSO, but the denial—now under appeal—introduces regulatory uncertainty and potential delays to market entry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
current report

FAQ

What is the current stock price of Cytosorbents (CTSO)?

The current stock price of Cytosorbents (CTSO) is $1 as of July 2, 2025.

What is the market cap of Cytosorbents (CTSO)?

The market cap of Cytosorbents (CTSO) is approximately 75.1M.

What is the primary focus of CytoSorbents Corporation?

CytoSorbents Corporation specializes in blood purification therapies for critically ill and cardiac surgery patients, using proprietary polymer adsorption technology to reduce inflammation and manage cytokine storms.

How does CytoSorbents' flagship product work?

The flagship product, CytoSorb®, utilizes highly porous polymer beads to adsorb inflammatory cytokines and other harmful molecules, thereby mitigating the risk of organ failure in critical care settings.

In which clinical settings are CytoSorbents' products typically used?

Their products are primarily used in intensive care units and during or after cardiac surgery, where the management of excessive inflammation and cytokine release is crucial to patient outcomes.

What distinguishes CytoSorbents from other medical device companies?

CytoSorbents is distinguished by its focused expertise in blood purification and cytokine adsorption, backed by a strong clinical validation process and international regulatory approvals in the European Union.

What are the main revenue channels for this company?

Revenue is generated primarily through direct sales of their core products, complemented by collaborations with distributors, strategic partners, and engagements with government agencies and research grant programs.

How does the company ensure the safety and efficacy of its technology?

The safety and efficacy are achieved through rigorous engineering of biocompatible polymer beads, extensive clinical testing, and continual refinement based on feedback from healthcare professionals and research institutions.

How does CytoSorbents contribute to the management of cytokine release syndrome?

By effectively removing excess cytokines from the bloodstream, CytoSorbents' technology helps to control the systemic inflammatory response, reducing complications such as organ failure in life-threatening conditions.
Cytosorbents Corp

NASDAQ:CTSO

CTSO Rankings

CTSO Stock Data

75.13M
53.25M
9.72%
29.71%
2.97%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
PRINCETON